Allosteric Modulation by Persistent Binding of Xanomeline of the Interaction of Competitive Ligands with the M1 Muscarinic Acetylcholine Receptor
Open Access
- 1 June 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 301 (3) , 1033-1041
- https://doi.org/10.1124/jpet.301.3.1033
Abstract
Xanomeline is a potent agonist that is functionally selective for muscarinic M1 receptors. We have shown previously that a significant fraction of xanomeline binding to membranes of Chinese hamster ovary (CHO) cells expressing the M1 receptors occurs in a wash-resistant manner and speculated that this persistent binding likely does not take place at the primary binding site on the receptor. In the present work we investigated in depth the pharmacological characteristics of this unique mode of xanomeline binding and the effects of this binding on the interaction of classical competitive ligands with the receptor in CHO cells that express the M1 muscarinic receptor. Onset of persistent binding of xanomeline to the M1 muscarinic receptor was fast and was only slightly hindered by atropine. Its dissociation was extremely slow, with a half-life of over 30 h. Although persistently bound xanomeline strongly inhibited binding of the classical antagonistN-methylscopolamine (NMS) to the receptor, there are multiple indications that this is not the result of competition at the same binding domain. Namely, wash-resistant binding of xanomeline only slightly slowed the rate of NMS association, but enhanced the rate of NMS dissociation. Moreover, preincubation with xanomeline followed by extensive washing brought about an apparent decrease in the number of NMS binding sites. Our findings are best interpreted in terms of allosteric interactions between xanomeline-persistent binding to the M1 muscarinic receptor and competitive ligands bound to the classical receptor binding site.This publication has 22 references indexed in Scilit:
- Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effectsPublished by Elsevier ,2004
- Annual Scientific Meeting of ASCEPT, 1999 From 'Captive' Agonism To Insurmountable Antagonism: Demonstrating The Power Of Analytical PharmacologyClinical and Experimental Pharmacology and Physiology, 2001
- The assessment of antagonist potency under conditions of transient response kineticsEuropean Journal of Pharmacology, 1999
- Assessing the distribution of parameters in models of ligand–receptor interaction: to log or not to logTrends in Pharmacological Sciences, 1998
- Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer DiseaseArchives of Neurology, 1997
- Exosites: their current status, and their relevance to the duration of action of long-acting β2-adrenoceptor agonistsTrends in Pharmacological Sciences, 1996
- Activation of muscarinic acetylcholine receptors via their allosteric binding sites.Proceedings of the National Academy of Sciences, 1996
- Muscarinic Receptors—Characterization, coupling and functionPharmacology & Therapeutics, 1993
- Muscarinic Receptor SubtypesAnnual Review of Pharmacology and Toxicology, 1990
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973